These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32787099)

  • 1. Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses.
    Ivashchenko AA; Mitkin OD; Jones JC; Nikitin AV; Koryakova AG; Ryakhovskiy A; Karapetian RN; Kravchenko DV; Aladinskiy V; Leneva IA; Falynskova IN; Glubokova EA; Govorkova EA; Ivachtchenko AV
    J Med Chem; 2020 Sep; 63(17):9403-9420. PubMed ID: 32787099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor.
    Todd B; Tchesnokov EP; Götte M
    J Biol Chem; 2021; 296():100486. PubMed ID: 33647314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir.
    Ivashchenko AA; Mitkin OD; Jones JC; Nikitin AV; Koryakova AG; Karapetian RN; Kravchenko DV; Mochalov SV; Ryakhovskiy AA; Aladinskiy V; Leneva IA; Falynskova IN; Glubokova EA; Govorkova EA; Ivachtchenko AV
    J Antimicrob Chemother; 2021 Mar; 76(4):1010-1018. PubMed ID: 33367751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
    Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
    Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.
    Yokoyama T; Sakaguchi H; Ishibashi T; Shishido T; Piedra PA; Sato C; Tsuchiya K; Uehara T
    Pediatr Infect Dis J; 2020 Aug; 39(8):706-712. PubMed ID: 32433222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
    Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
    Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cap-Snatching SFTSV Endonuclease Domain Is an Antiviral Target.
    Wang W; Shin WJ; Zhang B; Choi Y; Yoo JS; Zimmerman MI; Frederick TE; Bowman GR; Gross ML; Leung DW; Jung JU; Amarasinghe GK
    Cell Rep; 2020 Jan; 30(1):153-163.e5. PubMed ID: 31914382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
    Takashita E; Abe T; Morita H; Nagata S; Fujisaki S; Miura H; Shirakura M; Kishida N; Nakamura K; Kuwahara T; Mitamura K; Ichikawa M; Yamazaki M; Watanabe S; Hasegawa H;
    Antiviral Res; 2020 Aug; 180():104828. PubMed ID: 32574689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
    Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
    J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
    Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
    Shirley M
    Drugs; 2020 Jul; 80(11):1109-1118. PubMed ID: 32601915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.
    Taniguchi K; Ando Y; Kobayashi M; Toba S; Nobori H; Sanaki T; Noshi T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
    Omoto S; Speranzini V; Hashimoto T; Noshi T; Yamaguchi H; Kawai M; Kawaguchi K; Uehara T; Shishido T; Naito A; Cusack S
    Sci Rep; 2018 Jun; 8(1):9633. PubMed ID: 29941893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil.
    Yoshino R; Yasuo N; Sekijima M
    Sci Rep; 2019 Nov; 9(1):17464. PubMed ID: 31767949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
    Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
    Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review.
    Abed Y; Saim-Mamoun A; Boivin G
    Rev Med Virol; 2021 May; 31(3):e2175. PubMed ID: 32975358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple polymerase acidic (PA) I38X substitutions in influenza A(H1N1)pdm09 virus permit polymerase activity and cause reduced baloxavir inhibition.
    Jones JC; Pascua PNQ; Harrington WN; Webby RJ; Govorkova EA
    J Antimicrob Chemother; 2021 Mar; 76(4):957-960. PubMed ID: 33351916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural insights into the substrate specificity of the endonuclease activity of the influenza virus cap-snatching mechanism.
    Kumar G; Cuypers M; Webby RR; Webb TR; White SW
    Nucleic Acids Res; 2021 Feb; 49(3):1609-1618. PubMed ID: 33469660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
    Baker J; Block SL; Matharu B; Burleigh Macutkiewicz L; Wildum S; Dimonaco S; Collinson N; Clinch B; Piedra PA
    Pediatr Infect Dis J; 2020 Aug; 39(8):700-705. PubMed ID: 32516282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.